Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged &#8805;60 years.

Yin, J Kevin; Pepin, Stephanie; van Aalst, Robertus; Loiacono, Matthew M; Samson, Sandrine I

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years.

Yin, J Kevin; Pepin, Stephanie; van Aalst, Robertus; Loiacono, Matthew M; Samson, Sandrine I.

Affiliation

Yin JK; Global Medical Affairs, Sanofi, Singapore.
Pepin S; Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
van Aalst R; Global Clinical Sciences, Sanofi, Lyon, France.
Loiacono MM; Department of Modeling, Epidemiology and Data Science, Global Medical Affairs, Sanofi, Lyon, France.
Samson SI; Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.

Hum Vaccin Immunother ; 18(6): 2106749, 2022 Nov 30.

Article de En | MEDLINE | ID: mdl-35914122

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins antigrippaux / Grippe humaine Limites: Humans / Middle aged Langue: En Journal: Hum Vaccin Immunother Année: 2022 Type de document: Article Pays d'affiliation: Singapour Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google